The price of Cidara Therapeutics Inc (NASDAQ: CDTX) closed at $0.76 in the last session, up 6.85% from day before closing price of $0.71. In other words, the price has increased by $+0.0489 from its previous closing price. On the day, 878526 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
We take a closer look at CDTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.55 and its Current Ratio is at 1.62. In the meantime, Its Debt-to-Equity ratio is 0.54 whereas as Long-Term Debt/Eq ratio is at 0.41.
On September 22, 2021, WBB Securities Upgraded its rating to Strong Buy which previously was Buy but kept the price unchanged to $6.25.
On March 04, 2021, Aegis Capital started tracking the stock assigning a Buy rating and target price of $9.Aegis Capital initiated its Buy rating on March 04, 2021, with a $9 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 11 ’24 when Tari Leslie sold 21,029 shares for $0.67 per share. The transaction valued at 14,085 led to the insider holds 258,681 shares of the business.
Sandison Taylor sold 20,662 shares of CDTX for $13,839 on Mar 11 ’24. The Chief Medical Officer now owns 347,095 shares after completing the transaction at $0.67 per share. On Mar 11 ’24, another insider, Ward Shane, who serves as the COO & CLO of the company, sold 20,473 shares for $0.67 each. As a result, the insider received 13,713 and left with 198,770 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDTX now has a Market Capitalization of 69.15M and an Enterprise Value of 24.84M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.22 while its Price-to-Book (P/B) ratio in mrq is 8.58. Its current Enterprise Value per Revenue stands at 0.44 whereas that against EBITDA is -0.81.
Stock Price History:
Over the past 52 weeks, CDTX has reached a high of $2.10, while it has fallen to a 52-week low of $0.59. The 50-Day Moving Average of the stock is 0.7011, while the 200-Day Moving Average is calculated to be 0.8684.
Shares Statistics:
According to the various share statistics, CDTX traded on average about 713.47K shares per day over the past 3-months and 631.07k shares per day over the past 10 days. A total of 90.62M shares are outstanding, with a floating share count of 81.82M. Insiders hold about 9.71% of the company’s shares, while institutions hold 29.88% stake in the company. Shares short for CDTX as of Feb 29, 2024 were 221.35k with a Short Ratio of 0.31, compared to 594.45k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.24% and a Short% of Float of 0.25%.
Earnings Estimates
The company has 3 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.1 for the current quarter, with a high estimate of -$0.07 and a low estimate of -$0.16, while EPS last year was -$0.19. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.28 and -$0.36 for the fiscal current year, implying an average EPS of -$0.31. EPS for the following year is -$0.58, with 3 analysts recommending between -$0.38 and -$0.7.
Revenue Estimates
According to 3 analysts, the current quarter’s revenue is expected to be $11.54M. It ranges from a high estimate of $14M to a low estimate of $6.7M. As of the current estimate, Cidara Therapeutics Inc’s year-ago sales were $10.22M, an estimated increase of 12.90% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $13.05M, a decrease of -49.80% less than the figure of $12.90% in the same quarter last year. There is a high estimate of $14.5M for the next quarter, whereas the lowest estimate is $11.6M.
A total of 3 analysts have provided revenue estimates for CDTX’s current fiscal year. The highest revenue estimate was $60.3M, while the lowest revenue estimate was $53M, resulting in an average revenue estimate of $57.85M. In the same quarter a year ago, actual revenue was $64.29M, down -10.00% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $21.07M in the next fiscal year. The high estimate is $29.5M and the low estimate is $5.8M. The average revenue growth estimate for next year is down -63.60% from the average revenue estimate for this year.
